Trials / Unknown
UnknownNCT04137588
Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
A Prospective of Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 126 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to explore the efficacy and safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Antiangiogenesis Agents | antiangiogenesis agents plus chemotherapy as first line treatment |
| DRUG | Immune checkpoint inhibitor | immune checkpoint inhibitor plus chemotherapy as first line treatment |
Timeline
- Start date
- 2021-03-03
- Primary completion
- 2022-03-01
- Completion
- 2022-06-01
- First posted
- 2019-10-24
- Last updated
- 2021-02-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04137588. Inclusion in this directory is not an endorsement.